Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Generation of transgene-free porcine intermediate type induced pluripotent stem cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of SSEA-1 expressing enhanced reprogramming (SEER) cells in porcine embryonic fibroblasts

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. ELMO3: a direct driver of cancer metastasis?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MR-vejledt laserablation til behandling af hjernetumorer og epilepsi

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Glioblastomas (GBM) are heterogeneous highly vascular brain tumors exploiting the unique microenvironment in the brain to resist treatment and anti-tumor responses. Anti-angiogenic agents, immunotherapy, and targeted therapy have been studied extensively in GBM patients over a number of decades with minimal success. Despite maximal efforts, prognosis remains dismal with an overall survival of approximately 15 months.Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, underwent accelerated approval by the U.S. Food and Drug Administration in 2009 for the treatment of recurrent GBM based on promising preclinical and early clinical studies. Unfortunately, subsequent clinical trials did not find overall survival benefit. Pursuing pleiotropic targets and leaning toward multitarget strategies may be a key to more effective therapeutic intervention in GBM, but preclinical evaluation requires careful consideration of model choices. In this study, we discuss bevacizumab resistance, dual targeting of pro-angiogenic modulators VEGF and YKL-40 in the context of brain tumor microenvironment, and how model choice impacts study conclusions and its translational significance.

Original languageEnglish
JournalCell cycle (Georgetown, Tex.)
Volume20
Issue number7
Pages (from-to)702-715
Number of pages14
ISSN1538-4101
DOIs
Publication statusPublished - Apr 2021

    Research areas

  • Angiogenesis, VEGF, YKL-40, glioblastoma, mouse models

ID: 65315764